700152Proof of Market for the Elumotion ExogloveClosedGRD Proof of MarketInnovate UKElumotion Ltd supplies market leading robotics and prosthetic electromechanical devices to diverse technology organisations, including: Touch Bionics, where Elumotion produced the initial design for their market leading hand prosthesis; Shunk, SciSys' Mars Rover and Bristol Robotics Lab. The company's expertise lies in developing highly cost-effective, humancompatible devices capable of human-equivalent motion. Elumotion’s portable humanoid robot hand (Elu2-Hand) is sold worldwide under licence though Schunk GmbH. This life-size hand has compact and lightweight joints within its volume fitted with actuators that approximate the torque and speed characteristics of human hand joints more closely than other robotic or prosthetic hands currently available. These mechanisms may be adapted to produce a powered control ‘glove’ (the Exoglove) able to actively move the operator’s fingers to reflect the position of the finger joints of the robot hand and vice versa and simulate touch sensation. The ExoGlove is a development of the Elu2- Hand IP offering valuable competitive solutions in significant, emerging global markets including: hazardous working environments, tele-surgery, hand rehabilitation, micro & macromanipulation, configurable industrial processes and gaming. Elumotion has built an Exoglove demonstrator to establish concept feasibility and now needs to select an initial target market and develop a product to meet its specific requirements. This Proof of Market project will research potential markets for Exoglove and will make a systematic and informed choice of market, application area and route to market. The project will identify any development work needed for the selected exploitation route and prepare exploitation plans including costs and schedule and document the investment case. The project will facilitate Elumotions' shift to an advanced engineering and product R&D lab, enabling recruitment, portfolio development and sales growth.